<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748993</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1_PII-05</org_study_id>
    <nct_id>NCT02748993</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Systemic Exposure and Efficacy of PAC-14028 in Children With Mild to Moderate Pediatric Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 and 2 study to assess the safety and efficacy of PAC-14028 cream in
      children with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of Investigator's Global Assessment (IGA)</measure>
    <time_frame>4 weeks</time_frame>
    <description>% of patients with IGA score of 0 (clear) or 1 (almost clear)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood concentrations of PAC-14028</measure>
    <time_frame>Day 1, Day 28</time_frame>
    <description>Blood concentrations of PAC-14028</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of IGA (Investigator's Global Assessment)</measure>
    <time_frame>1, 2, 4 week(s)</time_frame>
    <description>Change of IGA score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SCORAD (Severity Scoring of Atopic Dermatitis)</measure>
    <time_frame>1, 2, 4 week(s)</time_frame>
    <description>Change of SCORAD from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Change of EASI (Eczema Area and Severity Index)</measure>
    <time_frame>1, 2, 4 week(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction measurement</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>PAC-14028 Cream 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.1%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 Cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.3%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 Cream 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 1.0%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 Cream Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAC-14028 Cream Vehicle, twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 Cream 0.1%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 Cream 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 Cream 0.3%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 Cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 Cream 1.0%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 Cream 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 Cream Vehicle</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 Cream Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 24 months - 12 years

          -  Who was diagnosed with Atopic Dermatitis according to Haniffin and Rajka criteria,
             whose affected BSA is over 5% and IGA score is 2 (mild) to 3 (moderate).

          -  Who has applied stable amount of emollients daily before baseline visit

          -  Who voluntarily agreed to participate in the study and signed an informed consent
             form.

        Exclusion Criteria:

          -  Who has skin diseases other than atopic dermatitis or scar in the affected area which
             can affect the study, determined by the study investigators.

          -  Who has clinically significant medical history or diseases involving liver, kidney,
             neurological system, psychial disorder that can affect study results.

          -  Who has used systemic steroids, antibiotics, immunosuppressants, or received
             photochemical therapy within 28 days before study drug administration.

          -  Who has used topical steroids, immunosuppressants or antibiotics to treat atopic
             dermatitis within 14 days before study drug administration.

          -  Who has used or is expected to inevitably use prohibited concomitant medications
             during the study.

          -  Women who is pregnant /breast-feeding, or who has childbearing potential and does not
             use available contraceptives.

          -  Who has dosed other study medications within 30 days before screening.

          -  Who is determined ineligible for study participation by investigators for any other
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyuhan Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>November 18, 2018</last_update_submitted>
  <last_update_submitted_qc>November 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

